Nov 29, 2023 / 02:30PM GMT
Edward Andrew Tenthoff - Piper Sandler & Co., Research Division - MD & Senior Research Analyst
Good morning. My name is Ted Tenthoff. I'm a senior biotech analyst at Piper Sandler. And before I begin, I'm required to point out certain disclosures regarding the relationship between Piper and our next presenting company, Alnylam, which are posted at the back of the room and also at the registration desk. And that's a long time of disclosures. I remember doing the Alnylam IPO, it's one of the first ones that I did at Piper 20 years ago. So it really shows you the long relationship that we have with Alnylam.
As you know, Alnylam is a leading developer of RNA therapeutics with a growing commercial business and a rich pipeline of future therapies. After a roller coaster review, the FDA issued a CRL for ONPATTRO in hereditary and wild-type ATTR amyloidosis with cardiomyopathy, sending Alnylam shares lower. But I really want to own Alnylam right now for AMVUTTRA growth in the upcoming Phase III HELIOS-B data in early next year, which are positive, would expand the label and make up for the
Alnylam Pharmaceuticals Inc at Piper Sandler Healthcare Conference Transcript
Feb 06, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers